Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study

Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort

(2022) Arturo Ciccullo et al.   Viruses-Basel

Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens

(2022) Karam Mounzer et al.   Open Forum Infectious Diseases

Late cART Initiation Consistently Driven by Late HIV Presentation: A Multicenter Retrospective Cohort Study in Taiwan from 2009 to 2019

(2022) Chun-Yuan Lee et al.   Infectious Diseases and Therapy

Changing Pattern of Chemsex Drug Use Among Newly Diagnosed HIV-Positive Taiwanese from 2015 to 2020 in the Era of Treat-All Policy

(2021) Chun-Yuan Lee et al.   AIDS PATIENT CARE AND STDS

Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis

(2021) Anthony Allen Reeves et al.   SEXUALLY TRANSMITTED INFECTIONS

Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV

(2021) Arturo Ciccullo et al.   Expert Opinion On Drug Safety

Cascade Analysis of Anonymous Voluntary HIV Counseling and Testing Among Patients with HIV Infection in Taiwan

(2020) Chun-Yuan Lee et al.   AIDS PATIENT CARE AND STDS

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

(2020) Chloe Orkin et al.   Lancet HIV

Overall tolerability of Integrase Inhibitors in clinical practice: results from a multicenter Italian cohort

(2020) Arturo Ciccullo et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Predictors of virological failure and time to viral suppression of first line integrase inhibitor based antiretroviral treatment

(2020) Ashima Pyngottu et al.   CLINICAL INFECTIOUS DISEASES

HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety

(2020) Kimberly K. Scarsi et al.   DRUGS

Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors

(2020) G Schuettfort et al.   HIV MEDICINE

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2020) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings

(2020) Daniele Armenia et al.   JOURNAL OF CLINICAL VIROLOGY

High prevalence of recreational and illicit drug use in German people living with HIV with a potential for drug–drug interactions with antiretroviral therapy

(2020) B Funke et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Antiretroviral adherence and virologic suppression in partnered and unpartnered HIV-positive individuals in southern Brazil

(2019) Marineide Gonçalves de Melo et al.   PLoS One

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) Hans-Jürgen Stellbrink et al.   Lancet HIV

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) David A Wohl et al.   Lancet HIV

Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs

(2018) et al.   CLINICAL INFECTIOUS DISEASES

Bictegravir

(2018) Vincenzo Spagnuolo et al.   Current Opinion in HIV and AIDS

Tolerability of integrase inhibitors in a real-life setting

(2017) Judit Peñafiel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up

(2017) Kuan-Yin Lin et al.   PLoS One

The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients

(2016) Hartmut B. Krentz et al.   AIDS PATIENT CARE AND STDS

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

(2016) C Hoffmann et al.   HIV MEDICINE

Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy

(2016) S. Scott Sutton et al.   PHARMACOTHERAPY

Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis

(2015) Olalekan A. Uthman et al.   ANNALS OF INTERNAL MEDICINE

Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review

(2015) Christian Manzardo et al.   Expert Review of Anti-Infective Therapy

Association of HLA-B*5701 Genotypes and Abacavir-Induced Hypersensitivity Reaction: A Systematic Review and Meta-Analysis

(2015) Wimonchat Tangamornsuksan et al.   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV

(2013) Calvin J Cohen et al.   BMJ Open

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

(2011) Sherene Min et al.   AIDS

Late presentation of HIV infection: a consensus definition

(2010) A Antinori et al.   HIV MEDICINE

HLA-B*5701 Screening for Hypersensitivity to Abacavir

(2008) Simon Mallal et al.   NEW ENGLAND JOURNAL OF MEDICINE